Lead-induced hypertension and cognitive dysfunction: brain amyloid pathology

Lead-induced hypertension and cognitive dysfunction: brain amyloid pathology

Abstract Background Lead (Pb) exposure is a recognized environmental risk factor for cognitive decline and may aggravate Alzheimer's disease (AD) pathology through hypertension-related mechanisms. However, the specific role of mineralocorticoid receptor (MR) signaling in this process remains un...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yunbo Zhang, Yao Xu, Yanling Song, Yachun Wang, Minghui Chen, Xinbo Ji, Yunyun Lin, Shenhong Gu
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Series:	European Journal of Medical Research
Subjects:	Alzheimer’s disease Pb Cognitive impairment Neuroinflammation Amyloid plaque Amlodipine
Online Access:	https://doi.org/10.1186/s40001-025-02965-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice
by: Dilpreet Kour, et al.
Published: (2025-03-01)

Neuro-Cells Mitigate Amyloid Plaque Formation and Behavioral Deficits in the APPswe/PS1dE9 Model of Alzheimer Disease While Also Reducing IL-6 Production in Human Monocytes
by: Johannes de Munter, et al.
Published: (2025-07-01)

Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
by: Daniela Dias, et al.
Published: (2025-01-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
by: I. A. Mazerkina
Published: (2025-04-01)

Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC
by: Kristian S. Frederiksen, et al.
Published: (2025-05-01)

Plasma amyloid‐β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort
by: Yuhan Xie, et al.
Published: (2025-01-01)

Faster decline of very prodromal dementia with Lewy bodies when amyloid positive
by: Frédéric Blanc, et al.
Published: (2025-04-01)

Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: A meta-analysis
by: Fatemeh Sedghi, et al.
Published: (2025-12-01)

Functional redundancy of the posterior hippocampi is selectively disrupted in non-demented older adults with β-amyloid deposition
by: Jenna K. Blujus, et al.
Published: (2025-06-01)

Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
by: Mohammed Alrouji, et al.
Published: (2025-06-01)

Compensatory enhancement of orexinergic system functionality induced by amyloid-β protein: a neuroprotective response in Alzheimer’s disease
by: Chenyu Zhuang, et al.
Published: (2025-03-01)

Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
by: Divya Bali, et al.
Published: (2025-06-01)

Head to head comparison of two PET/CT imaging agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in patients with alzheimer’s disease
by: David Alexoff, et al.
Published: (2025-06-01)

miR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain
by: Evgenia Salta, et al.
Published: (2016-08-01)

The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer’s Dementia: A Systematic Review
by: Alyaa Mostafa, et al.
Published: (2025-05-01)

Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment
by: YoungSoon Yang, et al.
Published: (2025-08-01)

Phototherapy via Modulation of β‐Amyloid in Combating Alzheimer's Disease
by: Yunhua Zhang, et al.
Published: (2025-05-01)

Chronic administration of prebiotics and probiotics prevent pathophysiological hallmarks of Alzheimer’s disease in the cortex of APP/PS1 mice
by: Giorgia Sarti, et al.
Published: (2025-05-01)

A Review Article on Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Alzheimer’s Disease
by: Dilip Raj Timalsina, et al.
Published: (2025-05-01)

Perspective: Minimally clinically important “symptomatic” benefit associated with disease modification resulting from anti‐amyloid immunotherapy
by: John Alam, et al.
Published: (2025-01-01)

Immune cell responses to amyloid-beta proteins: What is the extent and implications of amyloid-beta induced cytotoxicity in microglial cells and peripheral blood mononuclear cells?
by: Cao, A.
Published: (2017-07-01)

Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques
by: Lis de Weerd, et al.
Published: (2025-08-01)

Loss of kallikrein‐related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice
by: Kiwami Kidana, et al.
Published: (2018-01-01)

Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease
by: Abdolhossein Zare, et al.
Published: (2025-07-01)

Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice
by: Rui Mao, et al.
Published: (2025-06-01)

The role of monocytes and macrophages in the progression of Alzheimer’s disease
by: Wenyi Nie, et al.
Published: (2025-04-01)

The Role of Selected Flavonoids in Modulating Neuroinflammation in Alzheimer’s Disease: Mechanisms and Therapeutic Potential
by: Joanna Kruszka, et al.
Published: (2025-05-01)

Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption
by: Jonathan M. Schott, et al.
Published: (2025-05-01)

Alterações encontradas em cérebros de indivíduos acima dos 65 anos e sua correlação com demência de Alzheimer Changes found in the brain of people over 65 years old and their correlation with Alzheimer disease
by: Liana Lisboa Fernandez, et al.
Published: (1997-06-01)

Mechanotransduction Activates Microglia and Impairs Phagocytosis in Stiff Amyloid‐β Plaques
by: Yulin Liu, et al.
Published: (2025-08-01)

Amyloid-beta 40 as a biomarker of cognitive impairment in acute ischemic stroke
by: Aleksey A. Kulesh, et al.
Published: (2017-10-01)

CSF Amyloid-β42 associates with neuropsychiatric and cognitive outcomes via cerebral glucose metabolism
by: Ali Azargoonjahromi, et al.
Published: (2025-07-01)

Ethanol consumption aggravates amyloid pathology and neuroinflammation in Alzheimer’s disease associated with inflammasome activation and ASC speck propagation
by: Veronika Brezani, et al.
Published: (2025-07-01)

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
by: Cynthia J. Siebrand, et al.
Published: (2025-05-01)

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application
by: Nandhini Jayaprakash, et al.
Published: (2025-06-01)

ADVANCEMENT IN THE TREATMENT OF ALZHEIMER'S DISEASE, 2023
by: Anum Safdar, et al.
Published: (2024-03-01)

S100A8 Interaction with Amyloid-β Peptide Suppresses Its Fibrillation
by: Ekaterina Litus, et al.
Published: (2024-04-01)

Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
by: David Wilson, et al.
Published: (2025-07-01)

Human iPSC-derived cerebral organoids reveal oxytocin-mediated protection against amyloid-β pathology
by: Tomoki Asaba, et al.
Published: (2025-12-01)